Two Sigma Securities’s Inovio Pharmaceuticals INO Stock Holding History

Two Sigma Securities’s Portfolio INO Stock Details INO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-23,003	Closed	-$46.8K	–	1692
2025 Q2	$46.8K	Buy	+23,003	New	+$44.1K	0.01%	1117
2024 Q1	–	Sell	-9,038	Closed	-$55.3K	–	3261
2023 Q4	$55.3K	Buy	9,038 +1,503	+20%	+$7.42K	﹤0.01%	2589
2023 Q3	$35.2K	Sell	7,535 -1,897	-20%	-$10.5K	﹤0.01%	2510
2023 Q2	$50.5K	Buy	+9,432	New	+$76K	﹤0.01%	2392
2023 Q1	–	Sell	-1,880	Closed	-$35.2K	–	2950
2022 Q4	$35.2K	Buy	+1,880	New	+$42.6K	﹤0.01%	2206
2022 Q3	–	Sell	-4,172	Closed	-$87K	–	2840
2022 Q2	$87K	Buy	4,172 +1,942	+87%	+$54.7K	﹤0.01%	1777
2022 Q1	$96K	Buy	+2,230	New	+$100K	﹤0.01%	1809
2021 Q2	–	Sell	-1,431	Closed	-$159K	–	1591
2021 Q1	$159K	Buy	+1,431	New	+$188K	0.01%	668

Other funds holding INO

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BCM

Boxer Capital Management San Diego, California $762M AUM 1,125.36% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Two Sigma Securities's INO Position: Q3 2025 in Review

Two Sigma Securities sold out of Inovio Pharmaceuticals (INO) in Q3 2025, closing a stake of 23,003 shares — an estimated $46.8K sold.

Two Sigma Securities first reported a position in INO in Q1 2021 and held it in 8 quarters. The position peaked at $159K in Q1 2021. 99 funds tracked by Wall St. Rank hold INO as of Q3 2025.

Two Sigma Securities reported no remaining Inovio Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
Two Sigma Securities sold 23,003 Inovio Pharmaceuticals shares in Q3 2025, an estimated $46.8K.
Two Sigma Securities first reported a position in Inovio Pharmaceuticals in Q1 2021 and held it in 8 quarters.
Two Sigma Securities's Inovio Pharmaceuticals position peaked at $159K in Q1 2021.
99 funds tracked by Wall St. Rank held Inovio Pharmaceuticals as of Q3 2025.

Based on Two Sigma Securities's 13F filing for Q3 2025, filed 14 Nov 2025.